Semaglutide and liraglutide were derived from the native structure of GLP-1
If we block that signal and override it with medication, it doesnt stop the signal - it just redirects it
In clinical studies, liraglutide and semaglutide both led to an average 0.3-point drop in A1c in prediabetic participants (after 56 weeks for liraglutide 5 and 68 weeks for semaglutide 6 )a small but meaningful shift for people whose blood sugar is creeping upward toward the diabetes threshold
Body Composition (Beta) as part of Labs & Scans: an AI photo estimate of body fat percentage and muscle mass with a confidence level and a roughly 3 to 5 percent margin of error, plus DEXA scan import
Protein can also provide a sense of fullness, which will become more important as you transition off your GLP-1 treatment
Future direction: Multi target combination and cell therapy To overcome current limitations, the "central plan" intervention for GLP-1RA is moving towards the following directions: Multi target agonist development GLP-1/GIP/GCGR triple target agonists (such as Retatrutide) have entered phase III clinical trials, and their weight loss effect is expected to reach 22% -24%
